Advocating for Small Business Act

House Bill

H.R. 4449

119th Congress

Advocating for Small Business Act

Placed on the Union Calendar, Calendar No. 207.

Introduced:Jul 16, 2025

Primary Sponsor

Danny K. Davis

Representative

Democratic

IL-7

Cosponsors

2

Quick Stats

Policy Area

Health

Summary

This bill creates a commission to investigate and recommend ways to improve the security and production capacity of the United States' domestic pharmaceutical supply chain. The commission will look at issues like boosting domestic manufacturing, supporting the pharmaceutical workforce, and finding ways to make it easier for companies to sell products made in the U.S.

Latest Action

Referred to the Subcommittee on Health.

SponsorDanny K. Davis (D-IL)

Introduced7/16/2025

StatusPlaced on the Union Calendar, Calendar No. 207.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Advocating for Small Business Act

This bill creates a commission to investigate and recommend ways to improve the security and production capacity of the United States' domestic pharmaceutical supply chain. The commission will look at issues like boosting domestic manufacturing, supporting the

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill creates a commission to investigate and recommend ways to improve the security and production capacity of the United States' domestic pharmaceutical supply chain. The commission will look at issues like boosting domestic manufacturing, supporting the pharmaceutical workforce, and finding ways to make it easier for companies to sell products made in the U.S.

Bill Number: 4449
Sponsor: Danny K. Davis (D-IL)
Introduced: 7/16/2025
Status: Placed on the Union Calendar, Calendar No. 207.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Advocating for Small Business Act
Bill Number: 4449
Sponsor: Danny K. Davis (D-IL)
Status: Placed on the Union Calendar, Calendar No. 207.
Introduced: 7/16/2025
Summary: This bill creates a commission to investigate and recommend ways to improve the security and production capacity of the United States' domestic pharmaceutical supply chain. The commission will look at issues like boosting domestic manufacturing, supporting the pharmaceutical workforce, and finding w

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill creates a commission to investigate and recommend ways to improve the security and production capacity of the United States' domestic pharmaceutical supply chain. The commission will look at issues like boosting domestic manufacturing, supporting the pharmaceutical workforce, and finding ways to make it easier for companies to sell products made in the U.S.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Pharmaceutical Security Production ActThis bill establishes the Commission on Strengthening the Domestic Pharmaceutical Supply Chain.The commission must assess the security and vulnerabilities of the domestic pharmaceutical supply chain in the United States and recommend improvements, including by developing metrics for domestic manufacturing programs, proposing solutions to strengthen the domestic manufacturing workforce, and evaluating ways to support a financial market for domestically manufactured products.The commission terminates four years after the bill is enacted.

Key Points

Main provisions of the bill

Establishes a Commission on Strengthening the Domestic Pharmaceutical Supply Chain
The commission will assess vulnerabilities in the U.S. pharmaceutical supply chain and propose solutions to improve domestic manufacturing and production
The commission is required to develop metrics for domestic manufacturing programs and evaluate ways to support a financial market for U.S.-made pharmaceutical products
The commission will make recommendations to Congress and the President on how to strengthen the domestic pharmaceutical industry
The commission will terminate 4 years after the bill is enacted into law

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it could lead to changes that impact the pharmaceutical industry, healthcare providers, and consumers. The commission's work could result in new government programs or policies to boost domestic drug production, which could affect drug prices, availability, and supply chain reliability for both medical professionals and patients.

Policy Areas

Primary Policy Area

Health

Related Subjects

Advisory bodies

Congressional oversight

Manufacturing

Medical research

Prescription drugs

Research and development

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

4449, 119th Congress (2025). "Advocating for Small Business Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-4449

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.